Table 3

Demographic characteristics: placebo-controlled studies

Characteristic

Treatment group

Total, N = 2,319, n (%)

P value


DVPX, N = 1,327, n (%)

Placebo, N = 992, n (%)


Age, years

Mean ± SD

44 ± 18

44 ± 19


Least-squares mean

45

46

0.7454a


Range

10 to 100

9 to 99


5 to 17

15 (1)

12 (1)

27 (1)

0.1413b


18 to 24

131 (10)

83 (8)

214 (9)


25 to 30

140 (11)

138 (14)

278 (12)


31 to 64

855 (64)

617 (62)

1,472 (63)


≥65

186 (14)

142 (14)

328 (14)


Gender

Female

740 (56)

544 (55)

1,284 (55)

0.3087b


Male

587 (44)

448 (45)

1,035 (45)


Race

White Caucasian

1,109 (84)

825 (83)

1,934 (83)

0.4430b


Other

218 (16)

167 (17)

385 (17)


Participation duration, days

Mean ± SD

68 ± 84

57 ± 64

0.2344a


Least-squares mean

60

57


Range

1 to 400

1 to 391


aP value for the treatment group difference is from a two-way analysis of variance with the terms of treatment and study.

bP value for the treatment group difference is from the Cochran-Mantel-Haenszel general association test controlling for study.

DVPX = divalproex.

Redden et al. Annals of General Psychiatry 2011 10:1   doi:10.1186/1744-859X-10-1

Open Data